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ABSTRACT 
Since decades Tuberculosis (TB) has been a foremost cause of mortality and morbidity with more than one-third of the world population 
infected with latent TB. Recent fight with an age old disease continuously smack with a dawdling approach toward its treatment. In spite of 
extensive researches in this field for combating the disease we are lacking behind in race with its causing agent Microbacterium Tuberculosis. 
Multidrug (MDR) and extensively drug resistant (XDR) Mycobacterium tuberculosis creates the worldwide open threat to human welfare. Thus 
there is a need of swift researches for its combat. Here in this review we are giving a brief description towards various chemical agents which 
have been used for its therapy and new families arrived as a potential drug candidate till date.  
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1. INTRODUCTION 
Tuberculosis (TB), an airborne communicable disease and 
one of the three World Health Organization (WHO) priority 
infectious diseases, is caused by transmission of aerosolized 
droplets of Mycobacterium tuberculosis organism. Drugs for 
treating tuberculosis have been available for over half a 
century, and yet the incidence of disease worldwide 
continues to rise year by year.  
Statics 
In 2002, the statistics available estimated that 24,000 people 
developed active disease and close to 5,000 people died 
from TB every day.    
1 Co-infection with immunodeficiency virus is driving the 
increase in incidence2,3 and the cause of death in 31% of 
AIDS cases can be attributed to TB in the African region.4,5 
When coupled with the emergence of multidrug-resistant 
strains of Mycobacterium tuberculosis (MDR-TB),6 the scale 
of the problem becomes clear, as it will inevitably become 
even more difficult to treat TB in the future. It is now more 
than a decade since the World Health Organization declared 
TB “a global health emergency”.7 
The reasons for these problems are numerous.8,9  
Compliance with even the best available regimen is poor, 
and treatment failure is all too common. The need for new 
drugs is to extend the range of TB treatment options is acute. 
New chemical entities with novel mechanisms of action will 
most likely possess activity against MDR-TB.10 However, 
these alone will not provide the breakthrough that is 
needed. The key to improving therapy is to develop new 
agents with potent sterilizing activity that will lead to a 
shortening of the duration of chemotherapy.11 
1.1. The biology of Mycobacterium tuberculosis 
M. tuberculosis, the agent of human TB, was discovered in 
1882 by Robert Koch and for a long time called after his 
name (the Koch bacillus). Mycobacterium genus are Gram-
positive bacteria that share the property of acid-fastness 
(Ziehl-Neelsen staining), due to their mycolic acid rich cell 
wall structure. 
Mycobacterium is a genus of bacteria, which are slow 
growing, aerobic and distinguished by  
acid-fast staining and are obligate aerobes, characterized as 
gram-positive. The genus mycobacterium comprises the 
exceedingly pathogenic organisms that cause tuberculosis, 
Mycobacterium tuberculosis (M. tuberculosis) and sometimes 
M. bovis and M. leprae (leprosy).  
Tuberculosis (TB) is immensely infectious disease it reaches 
almost exclusively by airborne transmission. Although the 
disease can affect any site in the body, it most often affects 
the lungs. When pulmonary TB infected persons cough, their 
cough contains miniature droplet nuclei that enclose TB 
bacteria. These droplets remain suspended in the air for 
prolong duration. If someone who breathes in this 
contaminated air, can develop or be infected with TB.  
The cell wall of Mycobacterium species is essential for its 
growth and for continued existence in the infected host it is 
the most essential structural and functional component. In 
fact, this is the one of the most important drug target for 
some of the most efficient anti-mycobacterial drug 
molecules e.g. isoniazid and ethambutol. These chemical 
entities are known inhibitors of the biogenesis of cell wall 
which is in turn subjugated by covalently associated mycolic 
acids, few related arabinogalactan and peptidoglycan (AGP), 
based mycolic acids are accoladed by glycolipids such as α,α-
trehalose monomycolate (TMM).12 This permeability barrier 
based on mycolic acid screens the organism from 
environmental stress and enhance the contributes in disease 
perseverance and the refractoriness of M. tuberculosis to 
many known and potent antibiotics. A large amount of 
important macromolecular entities of mycobacterial cell 
wall is arabinan, it is a common constituent in 
arabinogalactan (AG) and lipoarabinomannan (LAM) both. 
In the chemical infrastructure of the mycolylarabino 
galactan-peptidiglycan complex, AG constitutes an integral 
part of proper cell wall, while LAM, foundation for a 
phosphatidylinositol anchor, apparently exists in a state of 
flux. LAM is an essential part of the cell envelope, which 
lacks covalent association with the cell wall core. Anchored 
in the cell membrane and traversing the cell wall, as well 
appearing as an excretory product, LAM has been implicated 
as a key surface molecule in host-pathogen interactions. The 
biosynthetic pathways leading to formation of the key 
mycobacterial cell wall components AG and mycolic acids, 
are the targets for the rational design of new antitubercular 
agents.  
The determination of the complete genome sequence of M. 
tuberculosis13 has had a profound effect on researchers in 
the TB field. New approaches are being followed that depend 
upon the availability of this information. These include 
detailed comparative genomics using bioinformatics, 
functional genomics, proteomics, transcriptomics, and 
structural genomics. Combined new tools for manipulating 
the genome of M. tuberculosis, offers a better understanding 
of the complex biology of this pathogen.  
1.2.     Multidrug resistant tuberculosis (MDR-TB)  
It refers to the simultaneous to at least Isoniazid (INH) and 
Rifampicin (RIF) with or without resistance to other drugs. 
Multidrug-resistance arises from the sharing of genes 
between different species or genera generally mediated by 
small pieces of extra-chromosomal DNA known as 
transposons or plasmids.14 Some antibiotics can actually 
induce the transfer of these resistance genes.15 Alternatively, 
as with the problematic multidrug-resistant M. tuberculosis 
(MDR-TB) strains accumulation of multiple point mutations 
in the chromosomal DNA can take place.16 Contamination of 
some commercial antibiotic preparations with the DNA 
(containing the inherent resistance genes) of the organisms 
that produce the antibiotic has been implicated as a source 
of drug resistance genes. The presence of DNA encoding 
drug resistance in antibiotic preparations has been proposed 
as a factor in the rapid development of multidrug resistance 
in bacteria.17 
1.3.    Extensively drug resistant tuberculosis (XDR-TB) 
XDR-TB, defined as extensively drug-resistant tuberculosis 
are cases of TB disease in persons whose M. tuberculosis 
isolates were resistant to isoniazid and rifampin and at least 
three of the six main classes of second-line drugs 
(aminoglycosides, polypeptides, fluoroquinolones, 
thioamides, cycloserine and p-aminosalicylic acid).18 XDR-TB 
is related to the poor management of multidrug resistant 
tuberculosis cases (which in turn is the consequence of 
poorly managed susceptible TB).19,20 As per the new 
definition of XDR-TB it is defined as the MDR-TB that is 
resistant to quinolones and also to any one of kanamycin, 
capreomycin or amikacin.21 The principles of treatment of 
MDR-TB and for XDR-TB are the same. The main difference 
is that XDR-TB is associated with a much higher mortality 
rate than MDR-TB, because of a reduced number of effective 
treatment options. The epidemiology of XDR-TB is currently 
not well studied, but it is believed that XDR-TB does not 
transmit easily in healthy populations, but is capable of 
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causing epidemics in populations which are already stricken 
by HIV and therefore more susceptible to TB infection.22 
1.4    Pathogenesis 
M. tuberculosis is an intracellular pathogenic bacterium, 
which has developed sophisticated mechanisms to survive 
inside host monocellular phagocytic cells and thus evade the 
immune system. TB bacilli usually multiply first in the 
macrophages in the lung alveoli and alveolar ducts and in 
draining lymph nodes. Infected macrophages eventually get 
killed, progressively creating a primary tubercle. Delayed 
cutaneous hypersensitivity develops and together with other 
cellular immune reactions leads to the caseous necrosis of 
the primary complex. CD4+ T-cells accumulate in great 
numbers in the early granulomatous lesions, where they are 
later joined by CD8+T-cells. Bacilli eventually spread to 
many parts of the body such as liver, spleen, meninges, 
bones, kidneys and lymph nodes, where they can either be a 
source of over disseminated TB or, more commonly, remain 
dormant. CD4+ T-cells play a major role in containment of 
infection: progressive TB is usually associated with a Th2 T-
cell response, whereas a pure Th1 response mediates 
protection. Th1 type cytokines, notably IFN-γ and TNF-α, are 
instrumental in walling off M. tuberculosis inside 
granulomatous lesions and controlling the evolution of the 
disease.23 In addition, T cells expressing a γδ T-cell receptor 
with specificity for small phosphorylated ligands and T-cells 
with specificity for glycolipids are stimulated.24,25 
Individuals with deficient IFN-γ signaling suffer from rapid 
evolution of the disease. Treatment with anti-TNF-α 
antibodies readily leads to tuberculosis reactivation in 
patients with rheumatoid arthritis.26 Granulomas persist for 
years and efficiently contain M. tuberculosis in a state of 
dormancy, as long as the host remains immunocompetent.27 
Occasional decline in cell-mediated immunity leads to 
reactivation tuberculosis, most frequently seen in adults as a 
pulmonary disease with infiltration or cavity in the apex of 
the lung. This is the most infectious form of TB.28  
1.5. Diagnosis  
Different diagnostic techniques have been adopted for 
identify the bacterium these are 
1. Tuberculin skin test (Mantoux tuberculin skin test)  
2. Interferon-gamma release assays (IGRA)  
3. Rapid sputum tests for tuberculosis (TB)  
4. New diagnostic technologies and tools 
2. CURRENTLY AVAILABLE DRUGS FOR THE 
TREATMENT OF TUBERCULOSIS 
To date, many drugs are available, which are classified into 
two categories. First-line therapy includes five medications: 
isoniazid (INH), pyrazinamide (PZA), ethambutol (EMB), 
rifampicin (RIF) and streptomycin.29,30 This regimen 
comprises daily isoniazid, rifampin, pyrazinamide, and 
ethambutol treatment for 2 months followed by 4 months of 
daily doses of INH and RIF.  
Second-line therapy, which is used exceptionally in the cases 
of drug resistance, includes cycloserine, capreomycin, 
fluoroquinolones, ethionamide, PAS, thioacetazone, 
rifabutin, tetramethyl piperidine substituted phenazines 
(TMP phenazines) and some macrolides.31 The second-line 
of drugs is clinically less effective and sometimes causes 
severe side effects; therefore, they are not often used in 
therapy.   
2.1.      First-line antitubercular drugs 
The first-line of drugs namely isoniazid, rifampicin, 
pyrazinamide, ethambutol and streptomycin are highly 
effective for short-term therapy. Figure 1 shows the site of 
action of first line drugs. (Table: 1) 
 
 
Figure 1:  An outline of Patent Protected drug targets of Mycobacterium tuberculosis. 
 
2.1.1. Isoniazid (1) (INH, 1952), is a 
highly potent drug for the treatment of 
tuberculosis. It is highly effective, 
inexpensive, well tolerated and readily 
available. It is very selective to 
mycobacteria and produces side effects in 
only 5% of patients. INH contains a pyridine ring and a 
hydrazide group and both moieties are essential for its high 
activity for M. tuberculosis. INH inhibits the synthesis of 
mycolic acids (long chain α-branched β-hydroxylated fatty 
acids) in M. tuberculosis by affecting the enzyme mycolate 
synthatase, which is unique for mycobacteria.32,33   
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Isoniazid is a prodrug which requires activation by the 
mycobacterial catalase peroxidase enzyme (kat G) to 
generate a range of both reactive radicals (hydrogen 
peroxide, superoxide, peroxynitrite and hydroxyl radical) 
and reactive organic radicals such as isonicotinic acyl radical. 
These radicals then attack multiple targets (e.g. mycolic acid 
synthesis, DNA damage, lipid peroxidation and NAD 
metabolism) in the tubercle bacillus.34 It is orally active and 
exhibits bacteriostatic action on resting bacilli and is highly 
active against the M. tuberculosis complex (M. bovis, M. 
africanum and M. microti). It has very low MICs (0.02-0.06 
µg/mL)35 against these pathogens. INH enters the organism 
by diffusion and oxygen dependent active transport36,37 and 
is reported to have an effect on almost every aspect of 
mycobacterial metabolism. A mutation within the 
mycobacterial INH-A gene was shown to confer resistance to 
both INH and ethionamide in M. smegmatis and in M. bovis, 
suggesting that the INH-A is the likely target of this drug and 
related reagents.38  
The patented targets against which antitubercular drugs can 
be developed are shown in boxes. These targets are known to 
control various cellular processes required for survival or 
virulence of M. tuberculosis. The site of action of first-line 
drugs (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol and 
Streptomycin) are shown by arrows. (Adapted from : Vohra R., 
Gupta M., Chaturvedi R., Singh Y., Recent patents on Anti-
Infective Drug Discovery, 2006, 1, 95-106.) 
2.1.2. Rifampicin (2) (RIF, 
1965), belongs to rifamycin  
group of semisynthetic 
antibiotics isolated from 
Streptomyces mediterrani,39 
characterized by a natural 
ansa structure (chromophoric 
naphthohydroquinone group 
spanned by a long aliphatic 
bridge), are potent inhibitors 
of prokaryotic DNA-dependent RNA polymerase, an enzyme 
necessary for RNA synthesis.40 RIF acts on β-subunit of this 
enzyme resulting in the formation of a stable complex. This 
in turn, causes inhibition of bacterial RNA synthesis and has 
no effect on mammalian enzymes. RIF specifically inhibits 
the transition from synthesis of short oligoribonucleotides to 
full length transcripts. Isolating RNA polymerase from M. 
smegmatis, it has been demonstrated that RIF specifically 
inhibited the elongation of full-length transcripts and had 
virtually no effect on the initiation of transcription.41 The 
lipohilic properties of the molecule are important for the 
binding of the drug to the polymerase and aid in the 
penetration of the drug across the mycobacterial cell wall. To 
avoid rapid development of bacterial resistance, RIF is 
recommended in combination with other first-line agents 
either isoniazid or ethambutol. However, a combination of 
INH and RIF may increase a risk of hepatotoxicity. RIF is 
effective against M. tuberculosis with MIC ranging from 0.1 to 
0.2 μg/mL.42 
2.1.3. Streptomycin (3) 
(1944), an aminoglycoside 
antibiotic derived from 
Streptomyces griseus made up of 
three components streptidine, 
streptose and N-methyl-L-
glucosamine, poorly absorbed 
from the gastrointestinal tract, is 
administered intramuscularly. 
Streptomycin was the first really 
effective drug against TB, and 
dihydrostreptomycin has almost 
the same antibacterial activity as the parent compound. It 
has an MIC value of 1 µg/mL with 50-60% plasma protein 
bound and a half life of 5-7 hr. It penetrates the inner 
membrane of   M.tuberculosis and binds to the 30S subunit of 
the ribosome.4343 Mutations in the rpsL gene of the ribosomal 
S12 protein of mycobacteria or base substitutions in the 16S 
rRNA region confers resistance to streptomycin. Different 
synthetic derivatives of streptomycin have been synthesized 
and evaluated against M. tuberculosis.44,45,46 Due to the toxic 
effects on peripheral, central nervous system at higher 
dosage and hypersensitivity reaction, streptomycin is not a 
popular choice for treating tuberculosis.  
2.1.4. Pyrazinamide (4) (PZA, 1970) a structural 
analogue of nicotinamide, is first-line drug of short-course 
TB therapy. It is also active against semidormant bacilli not 
affected by any other drug, has strong synergy with INH and 
RIF and shortens the therapy period to 6 months.47, 48 The 
drug has no significant bactericidal effect and is thought to 
act by sterilizing effect.49 The activity of 
PZA depends on the presence of 
bacterial amidase which converts PZA 
to pyrazinoic acid, the active anti-TB 
molecule. Resistance to PZA is usually 
accompanied by loss of 
pyrazinamidase activity in M. 
tuberculosis. The gene pncA encoding the M. tuberculosis 
pyrazinamidase has been sequenced, and mutations in pncA 
were found in smaller number of PZA-resistant M. 
tuberculosis strains.50  Mutations in pncA have been 
identified in PZA–resistant strains, and transformation of 
these strains with a functional pncA gene restored 
pyrazinamidase and PZA 
susceptibility.51 
2.1.5. Ethambutol (5) (EMB, 
1968) a synthetic amino alcohol 
(ethylene diamino-di-1-butanol) 
52, 53, 54 with profound 
antimycobacterial activity, is 
orally effective bacteriostatic agent that is active against 
most strains of  Mycobacterium. Activity of EMB is 
stereospecific as dextro isomer exhibited maximum 
antitubercular activity (S,S form is 600 times more active 
than R,R). The target of ethambutol lies in the pathway for 
the biosynthesis of cell wall arabinogalactan. EMB 
specifically inhibits arabinosyl transfer, suggesting that 
arabinosyl transferase is primary cellular target for EMB. In 
the cell wall biosynthesis arabinosyl transferase III is 
responsible for the polymerization of arabinose into 
arabinan of arabinogalactan. The  genes  embAB  of  M. 
avium encode the drug target for ethambutol, the arabinosyl 
transferase responsible for the  polymerisation  of  arabinose  
into  the  arabinan   of    arabinogalactan and overproduction 
of this ethambutol-sensitive target leads to ethambutol 
resistance.55 
2.2.     Second-line antitubercular drugs 
Second-line antitubercular drugs are used due to drug-
resistance or to the non-availability of first-line drugs. 
(Table: 1) 
2.2.1. D-Cycloserine (6) (1955), 
chemically defined as D-4-amino-3-
isooxazolidone, D-cycloserine is derived 
from Streptomyces orchidaceus and is 
active against a broad spectrum of 
bacteria, including M. tuberulosis.56 It is a 
structural analog of the amino acid-
alanine, possesses activity against a wide range of bacteria, 
and inhibits M. tuberculosis at concentrations of 5-20 µg/mL. 
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D-cycloserine is well absorbed and distributed throughout 
the body following oral administration. As a mechanism 
based inhibitor it blocks PG biosynthesis by inhibiting the 
enzymes D-alanine racemase and D-alanilyl D-alanine ligase 
necessary for the synthesis of UDP-muramyl-pentapeptide. 
Which of these two enzymes is the main target of D-
cycloserine causing M. tuberculosis growth inhibition 
remains the matter of research.57, 58, 59,  Microorganisms 
treated with cycloserine accumulate a muramic-uridine-
nucleotide-peptide, which differs from that produced by 
mycobacteria in the absence of terminal D-alanine dipeptide. 
60, 61 Cycloserine produces severe side effects in the central 
nervous system that can also generate psychotic states with 
suicidal tendencies and epileptic convulsion. The drug is 
stable in alkaline solution but is rapidly destroyed when 
exposed to neutral or acidic pH. 
2.2.2. Ethionamide (7) (ETH, 1966) 
a derivative of isonicotinic acid, is 
bacteriostatic in nature. Ethionamide 
is useful for treating drug-resistant 
tuberculosis, but it causes frequent 
toxic side effects such as anorexia, 
vomiting, dysgeusia, neurological 
reactions and reversible hepatitis. In the last six years it was 
confirmed that this compound is a prodrug and is oxidized 
by ETH A (a flavoprotein monooxygenase).62, 63, 64, 65 
Oxidation of ethionamide by ETH A enzyme leads to a sulfinic 
acid which is likely to be further transformed to an amide 
and alcohol.63 Moreover, it had been known that the sulfinic 
acid produced was as active on mycobacterial growth in vitro 
as ethionamide.66, 67, 68, 69, 70 
2.2.3. The antitubercular activity of p-
aminosalicylic acid (8) (PAS) was reported 
in 1946, although it was synthesized long 
before.71 It is available in the form of sodium 
and calcium salt. p-aminosalicylic acid acts as 
an inhibitor of M. tuberculosis by impairing 
folate synthesis. Following DOTS (directly 
observed therapy, short course), it is rarely 
used today. However, it is occasionally used in the regimens 
for the treatment of TB caused by MDR-TB.72 The mode of 
action of this drug is still unclear, but previously it was 
suggested that it interferes with the salicylate-dependent 
biosynthesis of the iron chelating mycobactins involved in 
iron assimilation.73,74, 75, Recently, some of the M. tuberculosis 
strains resistant to this compound were found to have 
developed a reduced thymidylate synthase activity which 
interferes in fine with folate levels. But this study needs 
further investigation as direct inhibition of any enzyme has 
not yet been demonstrated and seven out of the ten clinical 
M. tuberculosis mentioned above did not have a reduced 
thymidylate synthase activity. 76 
2.2.4. Thiacetazone, (9) 
widely used drug in 
developing countries because 
of its easy availability and low 
cost, is sometimes used in 
combination with isoniazid 
for the treatment of tuberculosis. Thiacetazone is 
bacteriostatic and more toxic than other drugs, with fatal 
skin and gastrointestinal reactions being its more severe 
adverse effects. Thiacetazone like ethionamide suppresses 
the repression of the expression of ETH A which is at the 
source of this resistance. 77,78 In this case a sulfenic acid 
derivative and the carbodiimide were identified.64,65 
2.2.5. Capreomycin, (10) a complex cyclic peptide antibiotic 
derived from Streptomyces capreolus, capreomycin is 
administered intramuscularly. In addition, capreomycin has 
a mode of action, as well as pharmalocogical and toxicity 
profiles, similar to those of 
streptomycin. 
Capreomycin is the 
injectable drug of choice 
for the treatment of 
tuberculosis. It inhibits the 
protein synthesis through 
modification of ribosomal 
structures at the 16S rRNA.  
2.2.6. Fluoroquinolines (11) (FQ) have been used as 
therapeutic alternatives in MDR-TB. These compounds have 
a good distribution throughout the body tissues and fluids 
following oral administration. The main effects of 
fluoroquinolines are the 
inhibition of DNA supercoiling 
and damage to DNA, whose 
synthesis is rapidly 
interrupted. The action of 
quinolines on gyrase was 
determined from enzymatic 
and binding assays employing 
the purified E. coli enzyme as 
well as from examination of the sites in the genome that had 
undergone mutation when strains of E. coli became resistant 
to fluoroquinolones.79  
The fluoroquinolines such as ciprofloxacin are totally 
synthetic antibacterial agents. Derivatives recognized with 
activity against mycobacteria are ofloxacin, ciprofloxacin, 
sparfloxacin, levofloxacin, lomefloxacin etc. MICs of 
levofloxacin, ofloxacin and ciprofloxacin of about 1 µg/mL 
for M. tuberculosis have been reported.80 Moxifloxacin  (BAY 
12-8039) is an 8-methoxyquinolone and is one of the most 
active quinolones against bacteria with resistance to 
penicillins and macrolides, including Streptococcus 
pneumoniae, Haemophilus influenzae, Moraxella catarrahalis 
and M. tuberculosis.81, 82,83, 84,85 
2.2.7. Rifabutin (12) is a 
bactericidal antibiotic drug 
primarily used in the 
treatment of tuberculosis. 
The drug is a semi-
synthetic derivative of 
rifamycin. Its effect is based 
on blocking the DNA-
dependent RNA-
polymerase of the bacteria. 
The use of rifabutin is a 
matter of debate as, 
although in vitro, some M. 
tuberculosis strains 
resistant to rifampin are 
still sensitive to rifabutin, its routine clinical use in MDR 
cases has not demonstrated any further usefulness. 
2.2.8. Clofazimine (13) was first synthesized in 1954 as an 
anti-tuberculosis drug. In 1959 the 
drug was found effective against M. 
leprae and its use in the treatment of 
tuberculosis has been suggested.86 
However, no specific mechanism of 
action has been established but a 
recent study suggests a generalized 
membrane-disrupting effect.87 Its 
analogs tetramethyl piperidine 
substituted phenazines (TMP 
phenazines) are found to possess 
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significantly more activity against M. tuberculosis, including 
MDR clinical strains than clofazimines and the intracellular 
accumulation in mononuclear phagocytic cells, anti-
inflammatory activity, a low incidence of drug resistance and 
slow metabolic elimination rate, make clofazimines 
attractive candidate for the treatment of mycobacterial 
infections. The compounds of this series are active in vivo 
also.88, 89,90 One of the phenazines, B4169, potently inhibited 
the bacterium with MIC value of 0.015 µg/mL; the 
corresponding value for clofazimine was 0.06 µg/mL. 
Another phenazine B4128, showed significant intracellular 
activity (60% inhibition of growth) at 0.001 µg/mL against 
M. tuberculosis-infected monocyte derived macrophages and 
were superior to both clofazimine and rifampicin. B4157 a 
phenazinamine derivative displayed MIC 0.12 µg/mL as 
against 1.0 µg/mL for clofazimine.  
2.2.9. Macrolides (14) comprise a family of antibiotics 
ranging from erythromycin to many analogs synthesized 
recently. Erythromycin is a 14-membered macrolide 
consisting of a macrocyclic lactone ring attached to two 
sugar residues. Newer 
derivatives differ from 
the parent erythromycin 
in the size and/or 
substitution pattern of 
the lactose ring and 
include: roxithromycin, 
clarithromycin, azithromycin, rokitamycin and 
spiramycin.91,92, 93,94, 95 Although some of the macrolides 
display poor anti-microbial activity against enterobacteria, 
these can generally be regarded as broad spectrum agents 
inhibiting mycobacterial growth also. However none of them 
display interesting antitubercular activity. A number of 
semisynthetic derivatives with improved pharmacokinetic 
properties appear to be promising in the treatment of 
mycobacterial infections, particularly those caused by non-
TB species.96 These antibiotics bind to high-affinity site in the 
peptidyl t-RNA binding region of the bacterial 50S ribosome 
subunit causing dissociation of peptidyl t-RNA from 
ribosomes and inhibition of bacterial protein synthesis.97 
 
Table 1: Molecules in clinics their targets and toxic effects 
S. N.  Class of 
Compound 
Drug Target Toxicity Profile MIC 
1 Pyridine Isoniazid 
INH-1952 
Synthesis of mycolic acid, 
affects enzyme mycolate 
synthatase 
Mutation within mycobacterial 
INH- A gene 
0.02-0.06 
μg/mL 
2 Antibiotic Rifampicin 
RIF, 1965 
 
Semisynthetic 
antibiotic 
Streptomyces 
mediterrani 
Inhibitor of prokaryotic 
DNA-dependent RNA 
polymerase 
Combination of INH and RIF 
may increase risk of 
hepatotoxicity 
0.1 to 0.2 
μg/mL 
3 Antibiotic Streptomycin 
1944 
Aminoglycoside 
antibiotic 
Streptomyces griseus 
Binds to 30S subunit of the 
Ribosome 
Toxic effects on peripheral, 
CNS and hypersensitivity 
reactions 
1 μg/mL 
4 Structural 
analogue of 
Nicotinamide 
Pyrazinamide 
PZA, 1970 
 Mutation in pnc A have been 
identified in PZA resistant 
strains 
 
5 Amino Alcohol Ethambutol 
EMB, 1968 
Biosynthesis of cell wall 
arabinogalactan inhibits 
arabinosyl transfer   
  
6 Structural 
analogue of 
amino acid -
alanine 
D-Cycloserine 
1955 
 
Derived from 
Streptomyces 
orchidaceus 
Inhibit/ block PG 
biosynthesis 
Inhibit the enzymes D-
alanine racemase and D-
alanilyl D-alanine ligase 
Severe side effects in CNS that 
can also generate psychotic 
state wit suicidal tendencies 
and epileptic convulsion 
5-20 
μg/mL 
7 Isonicotinic 
acid 
Ethionamide 
ETH, 1966 
 Anorexia vomiting dysgeusia 
neurological reaction 
reversible hepatitis  
 
8 Amino acid p-aminosalicylic acid  
PAS, 1946 
Imparing folate synthesis 
 
Previously –interferes with 
the salicylate dependent 
biosynthesis of the iron 
chelating mycobactins 
involved in iron 
assimilation  
  
9  Thiacetazone Suppress the repression of 
the expression of ETHA 
More toxic than other fatal 
skin and gastrointestinal 
reactions 
 
10 Antibiotic 
 
Capromycin 
Cyclic peptide 
Inhibits the protein 
synthesis through 
Toxic profile as streptomycins  
O O O O
R
O
H
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 antibiotic 
Streptomyces 
capreolus  
modification of ribosomal 
structures at the 16S rRNA 
11 Fluoroquinoline
s  
Ciprofloxacin 
Ofloxacin 
Levofloxacin  
Inhibition of DNA 
supercoiling and damage to 
DNA 
 1 μg/mL 
12 Antibiotic Rifabutin 
Semi-synthhetic 
derivative of rifamycin 
Blocking the DNA-
dependent RNA-
polymerase of the bacteria 
  
13  Clofazimine 
1959 structural 
analogues 
Tetramethyl 
piperidine 
Substituted 
phenazines 
Membrane disrupting effect  0.06 
μg/mL 
14 Macrolides 
Antibiotic 
Erythromycin 
Roxithromycin 
Clarithromycin 
Azithromycin 
Spiramycin 
Inhibit mycobacterial 
growth 
  
 
3.  ANTITUBERCULARS DERIVED FROM NATURAL PRODUCTS     
Naturally occurring pure compounds as well as extracts 
from higher and lower forms of plants, microorganisms and 
marine organisms have indicated that inhibitory activity 
against MTB is widespread in nature. Many compounds 
isolated using preliminary functional assays have been 
provided from investigators interested in phytochemical 
biodiversity. Usually their potential pharmaceutical worth 
remains unknown since data to show that these compounds 
are adversely affecting mycobacterial survival mechanisms 
in humans, or have been derived from medicinal plants, is 
lacking. (Table: 2) 
3.1. & 3.2. Diterpenes continue to be valuable natural 
sources of antibacterials.  Antituberculous agents from West 
Indian sea whip Pseudopterogorgia elisabethae led to the 
discovery of two  benzoxazole     alkaloids,  
pseudopteroxazole (15)    and    seco-pseudopteroxazole 
(16).98 Pseudopteroxazole was found to effect potent 
inhibitory activity (97%) against M. tuberculosis  H37Rv  at  a  
concentration   of  12.5 µg/mL   and  seco-pseudopteroxazole 
inhibited 66% of mycobacterial growth. The potent activity 
was attributed, at least in part, to the benzoxazole 
functionality.  
3.3. & 3.4. Two novel serrultane diterpenes having 
antimycobacterial activity has also been isolated from the 
West Indian sea whip coral, Pseudopterogorgia elisabethae, 
namely, erogorgiaene (17) and 7-hydroxyerogorgiaene 
(18).99 Erogorgiaene induced 96% growth inhibition for M. 
tuberculosis H37Rv at a concentration of 12.5µg/mL and 7-
hydroxyerogorgiaene inhibited 77% of mycobacterial 
growth at a concentration of 6.25 µg/mL, respectively.  
3.5. Novel diterpene, elisapterosin B (19), possessing cage-
like elisapterane carbon skeleton, isolated from the hexane 
solubles of West Indian sea whip Pseudopterogorgia 
elisabethae Bayer displays strong in vitro antituberculosis 
activity. The tetracyclic carbon skeleton of the elisapterosins 
constitutes a new class of C20 rearranged diterpenes. In vitro 
studies on elisapterosin B showed strong inhibitory activity 
(79%) against M. tuberculosis H37Rv at a concentration 
12.5µg/mL.100,101 
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Table: 2 Natural products as antituberculars 
S.N
o. 
Class of 
compound 
Drug Isolaion MIC 
1 Diterpenes Benzoxazole alkaloids 
Pseudopteroxazole (15) 
 H37Rv  97% inhibition at 12.5 
μg/mL 
Pseudopteroxazole (16)  H37Rv  66% inhibition at 12.5 
μg/mL 
2 Serrultane 
Diterpenens  
Erogorgiaene (17) West Indian sea whip 
coral 
Pseudopterogorgia 
elisabethae 
H37Rv  97% inhibition at 12.5 
μg/mL 
7-Hydroxy erogorgiaene (18) H37Rv  77% inhibition at 6.25 
μg/mL 
3 Diterpene Elisapterosin B (19) West Indian sea whip 
Pseudopterogorgia 
elisabethae 
 
 
4.  COMPOUNDS  WITH ANTI-TB ACTIVITY IN PRECLINICAL TRIALS 
4.1. Fluoroquinolones, recently developed anti-TB 
compounds are being considered to be better in the 
treatment of MDR-TB infections. Among them CS-940 (20) 
and sparfloxacin showed the greatest antimycobacterial 
activities with inhibition of 50% of all the isolates at the 
concentrations 0.25-0.5 µg/mL. In vitro antimicrobial activity 
of CS-940 was tested against 761 clinical isolates.102  
 
4.2. PD 161148 (21) is a third generation 
fluoroquinolone selected from analysis of structure activity 
relationship (SAR), having potent activity against M. 
tuberculosis. It was observed that a C-8 methoxyl group 
enhances the bactericidal activity of quinolones with N1-
cyclopropyl substitution. 103 However, there is no 
information on the frequent side effects of fluoroquinolones 
such as complexation with metallic ions, phototoxicity and 
P450 inhibition nor on its rarer but life-threatening side-
effects such as renal, hepatic and cardiac toxicity. PD 161148 
and CS-940 were synthesized by Parke-Davis (originally but 
now Warner-Lambert) and Sankyo respectively.  Both PD 
161148 and CS-940 are amongst the most active of all third-
generation quinolones. But unfortunately there are no in vivo 
tuberculosis data in the public domain which would allow 
the two compounds to be further separated. 
4.3. Calanolide A, (22) is a naturally occurring 
pyranocoumarin104 of considerable interest because of its 
dual activity against TB and HIV infections.105, 106 The 
compound, an inhibitor of HIV-1 reverse transcriptase,107 is 
being progressed by Sarawak Medichem Pharmaceuticals 
and is in phase I/II developmental stage for the HIV 
indication. It also displays good in vitro activity towards M. 
tuberculosis. (+)-Calanolide A and (-)-Calanolide A 
demonstrated inhibitory antimycobacterial activity against 
M. tuberculosis H37Rv with 96 and 98% growth inhibition, 
respectively. The actual MIC for (+)-calanolide A was found 
to be 3.13 µg/mL. In a preliminary assessment of its activity, 
calanolide A was comparable to the positive control isoniazid 
and remained effective against rifampin- and streptomycin-
resistant TB strains.105 Sarawak has developed a process for 
the large scale synthesis of calanolide A thus reducing the 
dependency upon obtaining the material from scarce natural 
sources.105 Other analogues have been obtained either from 
plant extracts or by synthesis108 and some have been 
patented for their antimycobacterial properties.109  
4.4. In addition, Calanolide B, (23) which unlike 
calanolide A, is readily available in substantial quantities 
from renewable natural sources, e.g. from calophyllum seed 
oil,110 is claimed to have a similar spectrum of activity to 
calanolide A against mycobacteria and may be a more cost-
effective treatment.111 
4.5. The Ciba-Geigy 5-nitroimidazole derivative CGI 
17341 (24) showed considerable potential for the treatment 
of tuberculosis in preclinical studies.  In vitro, at 0.04 to 0.3 
µg/mL, the compound inhibited both drug-susceptible and 
multidrug-resistant strains of  M. 
tuberculosis and showed   no cross 
resistance with isoniazid, rifampicin, 
streptomycin or  ethambutol. Against 
M. tuberculosis in vitro, its activity 
was comparable to that of isoniazid 
and rifampicin and superior to 
streptomycin, ciprofloxacin, 
norfloxacin and the oxazolidinone DuP 721.  In M. 
tuberculosis - infected mice, oral treatment with CGI 17341 
on days 11 and 12 post infection resulted in an ED50 of 7.7 
mg/kg and a significant dose-dependent increase in survival 
time.112  
4.6. Poloxamer 315 (CRL-1072) (25) is a 
methyloxirane surfactant polymer from the CytRx 
corporation that appears to disrupt the cell membranes of 
microbes or their intracellular components. The highly 
purified polymer has been shown to be active against both M. 
tuberculosis113 and M. avium.114 In vitro studies against M. 
tuberculosis in broth culture show MIC values of 3.1-6.2 
µg/mL whilst, in a macrophage assay, these drop to 0.92 to 
1.25 µg/mL.115 The compound was active against strains of 
M. tuberculosis resistant to isoniazid, streptomycin and 
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rifampin. In vivo, 2 mg/kg/day of 315 administered 
intravenously three times a week for three weeks allowed 
survival of M. tuberculosis infected mice and reduced CFU 
(colony forming unit) counts in lungs and spleens by one to 
two log units. An IND (investigational new drug) has been 
obtained for this compound in the USA but as yet no plans 
have been made to progress the compound clinically.113 
4.7. The oxazolidones are a promising new class of 
synthetic antimicrobial agents with a unique mechanism of 
action in inhibiting protein synthesis.116 One compound, 
linezolid, has already reached the market place and other 
members of this class are in varying stages of 
development.117 The oxazolidones have activity against 
Mycobacteriun tuberculosis with linezolid  (U-100766) (26) 
inhibiting multi-resistant isolates in vitro at 2 µg/mL.118 This 
compound is amongst the very few fully artificial 
antibacterials targeting the 50S ribosomal subunit.119, 
120,121,122 However, the long term use of linezolid may be 
plagued with forbidding side effects.123,124  
4.8. PNU-100480 (27) an oxazolidone containing 
thiomorpholine moiety was active against M. tuberculosis 
with MICs of 0.125 µg/mL.125 
The Pharmacia Upjohn 
compound PNU-100480, was 
tested in a murine model 
against ten viable strains of  
M. tuberculosis in comparison 
to linezolid and isoniazid. 
When treatment was started 
one-day post infection and 
the compounds given by 
gavage for four weeks, PNU-
100480 proved comparable 
to isoniazid and more active than linezolid.126 
4.9. B4157127 (28) is phenazinamine derivative, 
closely related to the antileprosy drug clofazimine, which  
has been investigated at the University of Illinois as a 
potential treatment of 
tuberculosis.128 In vitro 
B4157 was tested against 
20 strains of M. 
tuberculosis, including 16 
drug-resistant strains and 
all were found to be 
susceptible to B4157. The 
MIC of B4157 at which 
90% of strains were 
inhibited were 0.12 μg/mL. 
In addition it prevented 
mortality and caused 
significant reduction of 
CFUs in the lungs and 
spleens. The animals 
treated with B4157 showed 
less pigmentation than 
those receiving clofazimine.  
4.10. Miconazole (29) 
is a well-established 
antifungal agent which has 
been reported to have anti-
TB activity in vitro (MIC 2 
µg/mL against M. 
tuberculosis H37Ra). The 
strength of the compound is 
that, as well as inhibiting 
replicating bacteria, it also has some effect on stationary 
phase bacilli129 Unfortunately, miconazole is not orally active 
and hence is of little further interest for progressing further. 
However, there are many 2nd and 3rd generation anti-fungal 
azoles which are clinically efficacious by the oral route, 
including the anti-fungal fluconazole which is much used in 
AIDS patients.130 
4.11. The anthelmintic drug niclosamide (30) was 
found to have anti-TB activity in vitro (MIC 0.5-1 µg/mL) 
against M. tuberculosis H37Ra. Besides being active against 
growing cells, it has the interesting property of acting against 
stationary phase non-replicating bacterial cells.129 However, 
although niclosamide has been extremely useful for the 
treatment of human tapeworm infections, it is not absorbed 
to any significant extent from the intestine. This explains 
why no systemic pharmacological effects are observed 
although the compound has been reported to be mutagenic 
in vitro and to have effects on sperm morphology in 
animals.131 This pharmacokinetic profile, along with its 
mutagenic capability, considerably blights the potential of 
this compound for TB chemotherapy. 
4.12. Rifamycin derivative CGP 7040 (31), has been 
compared in vitro to rifampicin against rifampicin-sensitive 
and  rifampicin-resistant strains of M. tuberculosis and M. 
avium / intracellulare / scrofulaceum (MAIS) complex. The 
compounds had MICs 4 to 8 times lower than those of 
rifampicin against sensitive       M. tuberculosis strains.132 
Overall CGP7040 was more active than rifabutin and 
rifampicin against M. avium and was superior to rifampicin 
towards M. tuberculosis. In addition it was found to be 
considerably more stable than rifampicin.133 However, 
preclinical studies in collaboration with the University of 
Colorado were terminated and the compound is not available 
for licensing.134 
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Table: 3 Compounds with anti-TB activity in preclinical trials 
S. 
No. 
Class of compound Molecule S. N. Class of compound Molecule 
1 Fluoroquinolones CS-940 (21) 8 Oxazolidones Linezolid  (U-100766) 
(27) 
 
2 IIIrd generation fluoroquinolone PD 161148 (22) 
 
9 Oxazolidones PNU-100480 (28) 
 
3 Pyranocoumarin Calanolide A, (23) 10 Phenazinamine B4157129 (29) 
4 Pyranocoumarin Calanolide B, (24) 11 Imidazole   
 
5 5-nitroimidazole CGI 17341 (25) 12 Amide Niclosamide (31) 
6 5-nitroimidazole PA 824 (26), 13 Rifamycin derivative CGP 7040 (32) 
7 Methyloxirane surfactant 
polymer 
Poloxamer 315 (CRL-
1072) 
 
   
 
5. COMPOUNDS WITH ANTI-TB ACTIVITY IN 
CLINICAL TRIALS 
Regardless of the severe occurrence of TB along with the rise 
of MDR strains, progression to discover a new vaccine or 
improvement of current BCG vaccine has been very slow.135 
In recent drug discovery program there are several new 
drug candidates developed, which have arrived at early 
stages of clinical trials (Table 4).20 Among many active 
profiles discovered only a couple of the compounds are in 
phase I or II clinical trials and few of the compounds have 
entered phase III clinical trials. Following discussion will 
provide the detailed information of each clinical candidate. 
5.1. The Baeyer quinolone moxifloxacin (BAY12-
8039)136 (32) is the newest member of this 4th generation 
class of antibiotic 
progress through the 
clinical pipeline. It has 
recently been launched in 
Germany (1999) for the 
treatment of respiratory 
tract infections.137 The 
drug has been shown to 
be active against M. 
tuberculosis in vitro and in 
vivo in various test systems.138, 139 Against M. tuberculosis 
CSU93, a highly virulent, recently isolated clinical strain, the 
MIC of moxifloxacin was 0.25 µg/mL. Oral administration of 
drug to mice at 100 mg/kg produced peak serum 
concentrations of 7.8 µg/mL within 15 minutes of dosing. On 
this basis, mice were infected with a sublethal inoculum of 
M. tuberculosis CSU93 and then treated with moxifloxacin at 
100 mg/kg per day for 8 weeks. This resulted in a significant 
decrease in the log 10 CFU counts in the organs of treated, 
compared to untreated, mice – 0.6 + 0.2 versus 5.65 + 0.3 in 
the lungs and 1.5 + 0.7 versus 4.9 + 0.5 in the spleens, 
respectively (p < 0.001 in both organs).140 In other studies in  
M. tuberculosis H37Rv-infected mice, orally administered 
moxidectin at 100 mg/kg/d given six times weekly was as 
bactericidal as isoniazid at 25 mg/kg over a similar dosing 
schedule.138 It was also demonstrated that 8 weeks of 
treatment with moxifloxacin (100 mg/kg/d) or with 
moxifloxacin plus isoniazid (100 mg/kg and 25 mg/kg, 
respectively per day) sterilized the lungs in seven of eight 
and eight of eight mice, respectively. Furthermore, the 
elimination half life of the drug in man, mean value 12 
hours140 (compare isoniazid – 1 to 2 hours) supports the 
possibility of once-a-day treatment. 
 
5.2. The Daiichi quinolone Sitafloxacin (DU-6859a)141 
(33) is in Phase III trials in both Japan and the USA.142 The 
compound has outstanding 
activity against a broad range 
of bacteria. When compared 
to a number of other 
quinolones – ciprofloxacin, 
levofloxacin, gatifloxacin and 
moxifloxacin – sitafloxacin 
was the most active against 
3344 gram-positive cocci and 
406 anaerobes, and against 
5046 gram-negative bacteria it either equalled or bettered 
clinafloxacin.143 The mechanistic basis for this potency is 
believed to reside with sitafloxacin’s ability to equally inhibit 
both DNA gyrase and topoisomerase IV, and its IC50s against 
these enzymes were amongst the lowest of the 
quinolones.144 Sitafloxacin was equipotent with gatifloxacin 
and sparfloxacin, and more active than levofloxacin and 
ofloxacin, when tested against M. tuberculosis - MICs at 
which 90% of strains of M. tuberculosis  inhibited (MIC90s) 
were 0.2 µg/mL.145, 146 No data appear to have been 
published for the activity of the compound against M. 
tuberculosis  in vivo. In clinical studies of sitafloxacin in 
healthy volunteers oral bioavailability was at least 70%; it 
was well tolerated with no serious adverse effects and the 
elimination half life was 4.4 to 5 hours. A study in which the 
postantibiotic effect was determined for sitafloxacin (and 
several other quinolones) against various bacteria 
concluded that this factor would permit dosing on a once 
every 24 hours basis.147 
5.3. Gemifloxacin (34) is another quinolone in the late 
stages of development and 
it is being progressed by 
SmithKline Beecham on 
license from LG Chem. 
Following various Phase III 
trials, it has now been 
submitted for approval in 
the USA for the treatment of 
respiratory infections.148, 
149 In healthy volunteers, 
oral bioavailability is approximately 70%, it is well tolerated 
and has a mean elimination half life of 7.4 hours. These 
characteristics, coupled with its potent antibacterial activity 
suggest its suitability for a once-daily dosing regimen.150 
Data on the anti-TB potential of gemifloxacin appear to be 
limited to a report comparing it activity to five other 
quinolones against 250 clinical isolates of M. tuberculosis  
susceptible or resistant to first-line antituberculosis drugs. 
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In these assays, gemifloxacin showed a MIC90 value of 8 
µg/mL, compared with 1 µg/mL for levofloxacin, 
trovafloxacin and grepafloxacin.151 
5.4. T-3811ME (35) is unique amongst other broad-
spectrum quinolones 
as it lacks the 
presence of a 
fluorine atom at the 
6-position of the 
ring. But shows 
similar broad 
spectrum and potent 
activity against 
bacteria as the best of the fluoroquinolones.152 Against ten 
strains of M. tuberculosis, T-3811ME has an MIC90 value of 
0.0625 µg/mL – comparable with ciprofloxacin and 
levofloxacin, and more active than trovafloxacin. No other 
TB relevant data appear to have been published but the 
compound is being advanced for other bacterial indications. 
It is being progressed in the USA in collaboration with 
BristolMeyers Squib, with Phase II/III trials shortly to 
commence.153 
 Rifametane (SPA-S-565) (36) is a new semi-synthetic 
rifamycin being progressed by Societa Prodotti Antibiotici 
(SPA), Milan, Italy. It has a bactericidal spectrum and 
potency similar to that of rifampicin, but with much better 
pharmacokinetic properties.154 This is reflected in the fact 
that, although the MIC90 values of the two compounds were 
the same against 20 strains of M. tuberculosis, in TB-infected 
mice rifametane proved to be the more effective orally.155 In 
the healthy male volunteers, the pharmacokinetic and safety 
of a 300 mg single oral dose of rifametane were compared to 
a 300 mg dose of rifampicin.156 The elimination half life for 
rifametane was 10.58 hours compared with 1.89 hours for 
rifampicin, and the mean residence time was 10.58 hours for 
rifametane and 3.93 hours for rifampicin, and the mean 
residence time was 18.05 hours for rifametane and 3.93 
hours for rifampicin. In another Phase I trial carried out in 
collaboration with Glaxo India, a single oral dose of 150 mg 
was administered and the half-life and area under curve 
(AUC) were some 6 or 7-fold that of rifampicin. 
Encouragingly, serum drug levels above the MIC for M. 
tuberculosis were maintained for up to 48 hours after drug 
administration.157 Currently SPA are collaborating with 
Glaxo India in preparing to advance rifametane into Phase II 
trials.158  
5.5. Rifalazil KRM-1648, 3’-hydroxy-5’-(4-isobutyl-1-
piperazinyl)benzoxazinorifamycin159  (37) was found to be 
more potent than RIF and shortens the duration of 
treatment.160, 161, 162 It was synthesized at the Kaneka 
Corporation and shown to have superior activity to 
rifampicin against M. tuberculosis in vitro and in vivo.163 The 
compound was progressed clinically in association with 
PathoGenesis through Phase I trials in the USA, and into a 
Phase II trial in Brazil using pulmonary TB patients.164,165 
However, due to severe side-effects in the four-day Phase II 
trial, the development of rifalazil has been terminated.166 
5.6. The anti-mycobacterial activity of liposome-
encapsulated drug, MiKasome (38), has been found to be 
effective against M. avium infections in vitro and in animal 
models.167 In preclinical studies,168 48 hr after delivery to 
the lungs via liposome, over half of the antibiotic remained 
in this tissue. In animals, pharmacokinetic data showed that 
MiKasome produced 7-fold higher peak plasma levels 
compared to free drug (amikacin) administered 
intravenously. Additionally, the AUC was 150-fold higher 
with the liposomal material and a single dose of liposomal 
amikacin produced therapeutic levels of antibiotic for more 
than 72 hr.168  In preliminary clinical study, a patient with 
tuberculosis treated with MiKasome for 49 days exhibited 
negative culture.169 Pilot Phase II studies showed that 
MiKasome was able to resolve M. tuberculosis infections in 
adults and children who failed conventional therapies.  
5.7. Aconiazide (39) a prodrug of isoniazid which was 
designed to be less toxic than the parent drug. The latter is 
metabolized to hydrazine and acetylhydrazine, which have 
both been implicated in the toxicity of isoniazid. Because 
aconiazide is converted to 
isoniazid and 2-
formylphenoxy acetic 
acid, it was expected that 
the acid would bind to the 
isoniazid metabolites and 
so lower toxicity.170 This 
proved to be the case and 
aconiazide is indeed less 
toxic than the parent drugs and lacks carcinogenicity.170 In 
healthy patients it was found to produce proportionately 
lower levels of isoniazid in serum than the parent molecule 
itself.171 For sometime, further progression of the compound 
was delayed due to problems with its commercial synthesis. 
However, additional toxicology data are now being 
submitted to the FDA by Lincoln Diagnostics in order to 
conduct clinical trials in tuberculosis patients, and the 
compound has been granted Orphan Drug status in the 
US.172 
5.8. SRL 172 (40) is a preparation containing heat-
killed Mycobacterium vaccae and comprises Th1 adjuvant 
with bacterial antigens to induce host protective immunity. 
Extensive clinical studies on this immunomodulator are 
being conducted by SR Pharma for various indications 
including tuberculosis. In one study in Argentina it was 
added to routine chemotherapy in the treatment of 
pulmonary tuberculosis.173 Patients receiving SRL 172 (plus 
drugs) were found to have reduced sputum smear positivity 
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of AFB, increased weight gain and shortened time to 
becoming apyrexial, compared to drug treatment alone. It 
was concluded that the results indicated a switch to Th1 
immunological status and improved clinical status. Another 
study in 100 cases with relapsed or chronic tuberculosis 
showed SRL 172 to keep 97% of patients disease-free six 
months after treatment had finished, compared with 70% 
who received placebo. In other trials in tuberculosis 
patients, SRL 172 showed little difference, if any to those 
receiving placebo.174 
 
5.9. A diarylquinoline 
R207910 (41) has been 
identified as a potent anti-
TB compound that inhibits 
both drug sensitive and 
drug resistant M. 
tuberculosis in vitro having 
MIC 0.06 µg/mL.175 The investigation picked up this 
compound from the 20 interesting drug candidates which 
were identified after optimization by synthetic chemistry.176    
5.10. Sudoterb (LL-3858) (42) belongs to a class of 
compounds as pyrroles which are plant alkaloids. Sudoterb 
has been reported to have potent anti-TB activity in vitro 
and in vivo. In vitro sudoterb has bactericidal activity similar 
to isoniazid and is synergistic with rifampin. The 
combination of sudoterb with isoniazid, rifampin and 
pyrazinamide led to complete sterilization of both sensitive 
and MDR-TB strains in mice within two months and in 
combination with rifampin and pyrazinamide cured TB in all 
animals after three months. Sudoterb exhibits good oral 
bioavailability with once daily dosing. LL-4858 is the 
combination of LL-3858, isoniazid, rifampin and 
pyrazinamide.177   
5.11. One compound PA 824 (43), displayed MIC values 
ranging from 0.015 to 0.25 µg/mL against cultured 
replicating M. tuberculosis pan sensitive and rifampin mono-
resistant clinical isolates. It showed impressive efficacy 
when administered orally to 
both M. tuberculosis – 
infected mice and (25mg/kg) 
and guinea pigs (40 mg/kg), 
and was comparable to 
isoniazid at 25 mg/kg.178 In 
addition, it displayed low 
levels of toxicity with an cute 
toxic threshold value of >500 
mg/kg daily for 28 days. A 
bioreductive activation of PA 
824 by a combination of the 
low redox potential F420-dependent glucose 6-phosphate 
dehydrogenase and a previously unstudied protein 
(Rv3547) acting as the electron transfer mediator has been 
suggested.179  
5.12. Another nitroimidazole OPC67683 (Delamanid) 
(44) has successfully finished its phase II clinical studies and 
it demonstrates excellent in vitro activity for both resistant 
and nonresistant drug strains of M. tb in addition to this 
there is no cross-resistance to the first-line antitubercular 
drugs, consequently occasional and low dosing of the 
compound may be effective.180,181 This molecule has already 
completed a placebo-controlled phase II trial further the 
safety and pharmacokinetics properties in MDR refractive 
TB have also been done. 182, 183 
5.13. TMC207 (45) is bactericidal and it is tolerated 
very well during its initial clinical studies.60 Based on the 
promising phase I clinical trials, the compound TMC207 has 
entered into the phase II clinical trials.184 Tibotec Medicinal 
Compound 207 (TMC207) has emerged as a lead molecule 
out of this work and currently this compound is under phase 
II clinical assessment (Fig. 2). Detailed mechanistic study 
revealed that oligomeric (F ATPase) and proteolipic (V 
ATPase) subunit c of ATP synthase of mycobacteria is the 
target of this compound.79, 80 TMC207 is effective for 
resistant and nonresistant strains of M. tb at MIC 0.03 
μg/mL.79 The results of its clinical trials show that TMC207 
may shorten the treatment of TB and be effective in its 
treatment.185 
5.14. Quinolones have been classified as first generation 
(nalidixic acid, oxolinic acid, and cinoxacin), second 
generation (ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, 
and norfloxacin), third generation gatifloxacin, sparfloxacin, 
and levofloxacin), and fourth generation (moxifloxacin and 
trovafloxacin).186
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Table: 4 Compounds with anti-TB activity in clinical trials 
S. 
No
. 
Class of 
Compound 
Name of Active agent Target Stage of Development Funded 
agency 
1 4th generation 
class of 
antibiotic 
Baeyer quinolone 
moxifloxacin (BAY12-8039 
MIC of moxifloxacin was 
0.25 µg/mL. 
III Global TB 
Alliance/ 
Bayer 
2 Fluoroquinolon
e 
Gatifloxacin M. tuberculosis DNA 
topoisomerase II 
inhibitor 
III EU/ TDR 
3 Quinolone  Sitafloxacin (DU-6859a) inhibit both DNA gyrase 
and topoisomerase IV 
(MIC90s) were 0.2 µg/mL 
 
Phase III trials Daiichi 
4 Quinolone Gemifloxacin  MIC90 value of 8 µg/mL submitted for approval 
in the USA for the 
treatment of 
respiratory infections 
SmithKline 
Beecham on 
license from 
LG Chem 
5 Quinolones T-3811ME  MIC90 value of 0.0625 
µg/mL 
Phase II/III trials BristolMeyers 
Squib 
6 Semi-synthetic 
Rifamycin 
Rifametane (SPA-S-565)   Phase II Societa 
Prodotti 
Antibiotici 
(SPA), Milan, 
Italy 
7  Rifalazil KRM-1648, 3’-
hydroxy-5’-(4-isobutyl-1-
piperazinyl)benzoxazinorifa
mycin160   
 due to severe side-
effects in the four-day 
Phase II trial, the 
development of rifalazil 
has been terminated 
PathoGenesis 
8  MiKasome   Phase II  
9 Prodrug of 
isoniazid 
 Aconiazide   Orphan Drug status in 
the US 
 
10  SRL 172   SR Pharma 
11 Diarylquinoline R207910     
12 Pyrrole 
plant alkaloids 
Sudoterb (LL-3858)    
13 Nitroimidazoles OPC67683 Mycolic acid synthesis 
inhibitor (prodrug and 
requires activation 
III Otsuka 
14 Nitroimidazoles PA824 Protein synthesis 
Inhibition of Lipids 
II Global TB 
Alliance 
15 Diarylquinoline TMC207 ATP synthase subunit c 
proton pump 
II Tibotec 
J & J 
16  Ethylene 
diamine 
SQ109 Involved in cell wall 
synthesis inhibition 
II Scquella 
 
6. NEW ENTITIES DISCOVERED AND 
BIOEVALUATED FOR ATI-TUBERCULAR 
ACTIVITY 
Many different class of compounds are under inestigation 
for their bioactive potetial against antibacterial, specially 
anti-TB activity. Structural optimization of many diverge 
range of derivatives of following compounds (Table 5) by 
various groups across the globe has led to the identification 
and successfully synthesized for potent anti-TB activity 
profiling some of the compounds exhibiting significant 
activity against drug-sensitive strains of M. tb. Following are 
the major classes identified for the drug discovery venture.
 
Table: 5 New entities discovered and bioevaluated for ati-tubercular activity 
Quinoline derivatives Fluoroquinolone 
derivetives 
Diamine derivatives 
 
Pyrimidine derivatives 
 
Quinone derivatives 
 
Nitroimidazole 
derivative 
Terpenoids derivatives 
 
Purine derivatives 
 
Quinolone derivatives 
 
Oxazolidinones 
 
Isonicotinyl derivatives 
 
Sugar hybrids of aromatic and 
heteroaromatic aminoesters 
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7. DISEASE BURDEN AND THE JOB AHEAD  
Rising trends in the cases of tuberculosis infection have 
prompted a search for newer, more effective, less toxic drugs 
against drug-susceptible and resistant strains of 
tuberculosis. Despite most patients’ clearing their sputum of 
live bacteria two months after they are placed on oral 
therapy, the full six-month course is required to prevent 
relapse with active disease after therapy is discontinued.187, 
188 Decades of poor compliance with such a prolonged and 
complex regimen has had two unfortunate consequences: 
first, treatment of the disease is often unsuccessful, and 
tuberculosis continues to spread and cause immense 
mortality; and second, there is an expanding epidemic of 
drug resistance that threatens TB control programs 
worldwide.189, 190 Drug resistancein detection in such cases 
is not only challenging but time taking too – the method can 
take up to 35 days–and the wait means patients can be 
exposed to suboptimal treatment, and this ends up with 
MDR-TB. This is the major setback in controlling 
tuberculosis. Currently, at least 50 million people are 
estimated to be affected with MDR-TB. A little MDR strains 
of M. tuberculosis were establish as the resistant for several 
first-line chemotherapeutic agents as well as for few of the 
second-line drugs.191 Moreover, the high rate of coinfection 
with human immunodeficiency virus (HIV) presented a 
challenge to the existing chemotherapies. 
The ability of mycobacteria to survive in the environment 
and to persist in the host cell for prelong period of time 
makes it a successful pathogen. The cell-wall guards the 
bacteria and helps to promote their intracellular 
perseverance by inhibiting phagosome–lysosome fusion, 
keeping them sequestered away from terminal endocytic 
organelles.192 Latency too is an significant facet of TB 
pathogenesis. Mycobacteria release peripheral cell-wall 
lipids into their host cells, which induces the formation of 
granulomas that wall off the infection and limit its spread 
while restricting macrophage killing of the bacteria.193 
One such approach is the development of optimized 
compounds that are active against current targets. This 
strategy requires in-depth knowledge about the mode of 
action of the drug so that appropriate modifications in 
structure could lead to new active compounds. The second 
approach is based on the identification of newer targets, a 
strategy that would overcome the problem of multidrug 
resistance and offer effective control of drug-sensitive cases 
of tuberculosis as well. The basic requirement of the third 
strategy is to identify a crucial metabolic step whose 
interruption at any stage would make survival of the 
parasite very difficult. For example, enzymes involved in the 
cell wall biosynthesis pathway could provide a novel target 
for future drug discovery. 
Another potential route to decreasing the length of 
treatment would be to improve the potency of the currently 
used anti-tuberculosis agents. Such a strategy would allow 
higher effective dosing of patients and could thereby 
improve the therapeutic effect of the agent by maintaining 
the drug concentration above the MIC for longer periods of 
time or by enhancing the ratio of the peak concentration to 
the MIC. Drugs which affect the cell wall of the bacteria are 
known to have concentration-dependent cidal effects in vitro 
that may be achievable in vivo with enhanced potency. 
Since few years, at hand a remarkable progress is observed 
in understanding the biochemistry of M. tuberculosis, the 
disease progression, and the process by which a drug 
resistance mechanism works, and lots more in ascertaining 
the value of DOTS strategy in preventing treatment 
malfunctioning . Study in China has shown that cure rates as 
high as 95% can be achieved through DOTS 
implementation194  but treatment is labor intensive, making 
it difficult to deliver unless substantial infrastructure is in 
place. However, scarcity of appropriate efforts to develop 
new efficiently active chemical entities or rapid diagnostic 
procedures, and their significance to the global TB control is 
a point to be questioned.195  
Therefore, there is a serious requirement for the 
development of novel drugs or chemical entities that can act 
alongside of both i.e. actively growing and dormant bacteria 
with novel mode of action. The efforts for drug development 
are being coordinated by Global Alliance for TB Drug 
Development (www.tballiance.org), an organization which is 
involved in developing public-private partnerships since a 
long time to fetch out new faster-acting and reasonably 
priced drugs effective as antituberculars. The Alliance 
launched in 2000, aims to conquer the natural barriers to TB 
drug development procedure. Through working in joint 
venture with miscellaneous organizations such as academic 
institutions, government research organisations, non-
governmental bodies, the pharmaceutical manufacturing 
units and contract research companies, the GATB is 
supposed to plug gaps in the R&D pipeline. The efforts and 
policy will also encourage TB drug development by 
providing a outline in which the various elements of the 
process may be brought together.  
Rational development of a novel antitubercular agent 
actually calls for the exploration of new means to 
understanding of the genetics and physiology of M. 
tuberculosis. In this stare, the accessibility of the genome 
sequence of M. tuberculosis196 and potent genetic tools for 
manipulating mycobacteria have facilitated the valuable 
information about the potential targets. In addition to this, 
the information presented from X-ray crystallographic 
studies of numerous of these targets has assist for designing 
novel chemotherapeutic representative. 
Our research group has explored the chemistry of various 
heterocycles and their sugar hybrids and receieved 
overwhelming response in this direction, though many 
obstacle   The present state of knowledge provided vivid 
advances in understanding the biology, detailed 
biochemistry of the causing agent and intracellular lifestyle 
of mycobacterium, this precious wealth of information is 
supportive to undertake different targets for synthesizing 
new chemical entities which will be effective 
chemotherapeutics in drug development program against 
MDR-TB. The new authenticated and selective targets, 
attuned to high throughput assays against all forms of TB 
should be designed and synthesised for drug vulnerability 
testing, baseline screening (to discover new chemical leads), 
early drug resistance, and to direct retreatment plans for 
therapy. To get an early lead for developing new 
chemotherapeutics, idea of combinatorial and virtual 
libraries may prove very helpful, further in silico screening 
of the compounds must be on top priorities.13, 197  
Specifically, there are four areas where this extensive 
collaboration can supplementary advanced in moderanizing 
TB treatment ; in order to achieve the best results firstly, 
identifying new chemical candidates – the TB pipeline needs 
to be cherished and reinforced with additional promising 
chemical entities. Identifying and validating new drug 
targets, predominantly those related with the persistent 
state of Mycobacterium tuberculosis, is vital to screen and 
select novel compounds for development. Such compounds 
may already exist in libraries or may come from basic 
research discovery. Secondly, expanding clinical trial 
capacity – there is an urgent need to expand and improve TB 
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drug clinical trial capacity to evaluate new multi-drug 
regimens. The recent commitment by the European Union to 
fund clinical trial networks for AIDS, TB and malaria is an 
example of how donor countries can contribute, and 
endemic countries can work side-by-side with investigators 
to prepare and sustain the infrastructure necessary for 
ongoing clinical trials. Thirdly, advancing new technologies – 
the successful use of surrogate markers in the evaluation of 
HIV/AIDS therapeutics has demonstrated that valid 
surrogate and biomarkers can significantly reduce the length 
of clinical drug trials. Such markers must be developed for 
TB. Fourthly, ensuring regulatory harmonization – to avoid 
delays in the approval of new therapies and to accelerate the 
adoption of new TB drug regimens, TB-specific regulatory 
guidelines and their global harmonization are essential.  
Without new medicines, TB will only grow as a global threat, 
driven by its deadly synergy with HIV/AIDS, complicated by 
multi-drug resistant strains, and amplified by the 
consequences of poverty. When introduced alongside other 
advancements, such as diagnostics and vaccines, new drugs 
will expand the scope of current TB control and redefine 
public health targets.198,199, 200 
8. THE FUTURE OPPORTUNITY OF TB DRUG 
DEVELOPMENT 
The current regimens for treatment of drug sensitive TB are 
greatly uncomplicated when compared with the previously 
deviced TB treatment plan. It has been shortened from two 
years to six months but it still required a optimal regimen. 
The prolong exposure of a patient with immune suppressive 
condition cause severe harmful effects thus there is an 
urgent need to develop a two to three month regimen, the 
regimen must include once weekly dosing of three to four 
drugs. this can alter the results and will reduce the duration 
of treatment from 28 weeks to 8-12 to twelve weeks, 
moreover approximately 130 doses of a combination 
regimen will drop to 10 doses. This modification will 
appreciably pose a positive impact on treatment by 
improving patient adherence, and on development of drug 
resistance via improving treatment completion rates.201, 202  
Nanotechnology offers a unique opportunity in drug delivery 
system. Out of two major approaches the nanoparticle based 
technique is seems to be most promising approach.203, 204, 
205, In fact Nanoparticles tool emerged as valuable means in 
drug delivery owe to their high stability, viability of 
incorporation of both hydrophilic and hydrophobic 
components. The simplicity of the process involves 
parenteral administration in addition to oral and 
inhalational administration capability or probability. The 
competence of the treatment also proves when complete 
bacterial clearance from the organs is observed in M. 
tuberculosis infected mice treated with nanoparticles bound 
drugs. Free drugs cause bacterial clearance only after 
administration of 46 doses daily.206 Nanoparticle based  drug 
delivery is is particularly useful for targeted therapies 
intending to deliver drugs selectively to intracellular sites, 
like within macrophages, reticuloendothelial system or in 
monocytes, or in the areas where dormant persistent 
organisms accountable for prolonged treatment durations 
may be lodging.207, 208,209, 210, 211  
Liposomal formulations are also a novel delivery systems of 
TB drugs, but the prospective elasticity with nanoparticles 
poses superiority over liposome-encapsulated drugs. 
Another approach includes dry powder inhalers and 
nebulizers.212, 213 Aerosols of PA-824 based dry porous 
particle have been tested in low and high dosages which are 
eight-fold higher in concentration than its oral dose and the 
dose effects were compared with PA-824 oral 
administration for the treatment of guinea pigs tuberculosis. 
The results demonstrate a lower degree of inflammation and 
tissue damage. therefore this technique has a potential 
future in the treatment of tuberculosis.214203 In fact second 
line drug capreomycin formulation being used in the large 
porous particles form is being tested in human volunteers as 
an inhalational product, this chemical entity is in a Phase I 
study.210 Several other first-line drugs and few 
investigational agents have also been formulated and tested 
in an inhalational delivery system. Inhalational method 
distributes a large amount of drug dose to the lung, but the 
histological localization of increased delivery is yet too 
investigated. 
9. CONCLUSION 
In few decades, the investigation, research, and drug 
delivery approaches for the control of TB in under extensive 
progress. Loads of work regarding enrichment of the anti- 
TB activity or in finding new leads particularly active against 
MDR and XDR i.e. resistant mycobacterium strains is under 
exploration. All the efforts in this area are overwhelming and 
welcomed but still there is a need of novel persuasive drug 
targets and chemical entities which have strong, synergistic 
and complementary actions against a range of M. 
tuberculosis subpopulations which not only shorten TB 
treatment but also have high efficacy and low toxicity and in 
addition to this must be effective against MDRTB/XDR-TB 
and without doubt administered in concurrence with HIV.  
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